A61K31/28

ARTEMISININ-DERIVATIVE N-HETEROCYCLIC CARBENE GOLD(I) HYBRID COMPLEXES

The present invention relates to compounds of formula (I), which are artemisinin-derivative N-heterocyclic carbene gold (1) hybrid complexes, and to their therapeutic uses.

ARTEMISININ-DERIVATIVE N-HETEROCYCLIC CARBENE GOLD(I) HYBRID COMPLEXES

The present invention relates to compounds of formula (I), which are artemisinin-derivative N-heterocyclic carbene gold (1) hybrid complexes, and to their therapeutic uses.

Combination comprising N-acetyl-L-cysteine and its use

A combination of N-acetyl-L-cysteine, selenium in the form of selenomethionine and melatonin, and a medical product or pharmaceutical composition comprising such combination, useful for the treatment of a variety of diseases and conditions is described. The combination of N-acetyl-L-cysteine, selenium in the form of selenomethionine and melatonin is also useful for cosmetic treatment of skin and as an antibacterial agent.

Combination comprising N-acetyl-L-cysteine and its use

A combination of N-acetyl-L-cysteine, selenium in the form of selenomethionine and melatonin, and a medical product or pharmaceutical composition comprising such combination, useful for the treatment of a variety of diseases and conditions is described. The combination of N-acetyl-L-cysteine, selenium in the form of selenomethionine and melatonin is also useful for cosmetic treatment of skin and as an antibacterial agent.

THERAPEUTIC AGENT FOR UROLOGICAL CANCER WHICH IS CHARACTERIZED BY BEING ADMINISTERED WITH IL-6 INHIBITOR AND CCR2 INHIBITOR IN COMBINATION

Therapeutic agents and treatment methods for urologic cancers, particularly urologic cancers with reduced lysine (K)-specific demethylase 6A (KDM6A) function, the agents and methods being characterized by suppressing both IL-6 activity and CCR2/CCL2 activity, are provided.

THERAPEUTIC AGENT FOR UROLOGICAL CANCER WHICH IS CHARACTERIZED BY BEING ADMINISTERED WITH IL-6 INHIBITOR AND CCR2 INHIBITOR IN COMBINATION

Therapeutic agents and treatment methods for urologic cancers, particularly urologic cancers with reduced lysine (K)-specific demethylase 6A (KDM6A) function, the agents and methods being characterized by suppressing both IL-6 activity and CCR2/CCL2 activity, are provided.

Process for preparing supramolecular platinum-based compounds

The present invention is in relation to the fields of nanotechnology and cancer therapeutics. In particular, the present disclosure relates to improved methods for preparing lipid-conjugated platinum compounds with high purity and good yields. The present disclosure also relates to nanoparticles comprising lipid-conjugated platinum compounds with high drug loading efficiency for use in chemotherapy, and to methods for producing said nanoparticles.

Process for preparing supramolecular platinum-based compounds

The present invention is in relation to the fields of nanotechnology and cancer therapeutics. In particular, the present disclosure relates to improved methods for preparing lipid-conjugated platinum compounds with high purity and good yields. The present disclosure also relates to nanoparticles comprising lipid-conjugated platinum compounds with high drug loading efficiency for use in chemotherapy, and to methods for producing said nanoparticles.

aPKC INHIBITORS AND METHODS OF TREATING A NEURODEGENERATIVE DISEASE OR DISORDER

Provided herein are formulations effective for and methods of treating or preventing a neurodegenerative disorder in a subject in need thereof that can include administering an amount of an aPKC inhibitor to a subject in need thereof.

METHOD PREPARING SILVER-NANOCURCUMIN MATERIAL FOR INHIBITING NEW CORONAVIRUS
20220160673 · 2022-05-26 ·

The present disclosure provides a method preparing Silver-nanocurcumin material for inhibiting new coronavirus. The turmeric powder is heated and stirred and then mixed with silver nitrate solution. After multiple steps of cooling, stirring for reaction and centrifuging and other steps, crude extract of Silver-nanocurcumin is obtained. Then, after further processes such as the multiple washing and centrifuging, a purified composition of Silver-nanocurcumin is obtained. The composition of Silver-nanocurcumin can be used to inhibit the new coronavirus and its similar viruses, and as a source of drugs for the prevention and treatment of diseases derived from the new coronavirus COVID-19 in the future.